COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Overnight Fasting After Completion of Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03523377
Recruitment Status : Active, not recruiting
First Posted : May 14, 2018
Last Update Posted : June 12, 2020
Rockefeller University
University of California
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

The purpose of this study is to test whether regular not eating for at least 12 hours ("overnight fasting") can improve blood sugar and the health of the GI tract.

There are 2 parts to this study: Part 1 will last for 1-2 weeks and will determine whether the patient can participate in Part 2. If they complete Part 1 they are eligible to participate in Part 2, they will sign a separate consent form for Part 2. Part 2 of this study will last 6 months.

Interim 1 lasts 14 days and begins 10-17 days before Study Visit 1. During Interim 1, participants will complete 1-2 phone calls with study staff. During these calls, 24-hour food recalls will be performed. Staff will use the NCI supported 24-hour recall instrument (Appendix C) to facilitate the recall and enter dietary intake and timing of eating. Nightly fasting duration will be estimated from the 24-hour diet recall by calculating the elapsed hours between the last eating episode at night and the first eating episode the following day. Participants will also be reminded about the fecal collection during these phone calls.

During Interim 2, participants will complete one to three phone calls with study staff trained in motivational interviewing. These calls will be used to reinforce the prolonged overnight fasting instructions, identify barriers to prolonged overnight fasting, and support successes where they have occurred. Participants will also be prompted to send SMS text messages via the MSK Information Technology secure text messaging system (currently used in the clinical setting for wait time notification).

Condition or disease Intervention/treatment Phase
Childhood Cancer Survivors Other: prolonged overnight fasting Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The OnFACT study is a single-arm trial of prolonged overnight fasting among 50 overweight or obese adult survivors of childhood cancer followed in the Memorial Sloan Kettering Adult Long Term Follow Up Program.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Overnight Fasting After Completion of Therapy: The OnFACT Study
Actual Study Start Date : April 27, 2018
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021

Arm Intervention/treatment
Experimental: prolonged overnight fasting
The purpose of the intervention is to increase the nightly fasting duration to a minimum of 12 hours. Adherence to the intervention will be measured by the proportion of SMS text message-days reflecting 12 or more hours of fasting. The intervention protocol follows an approach using strategies outlined by social cognitive theory that focus on (a) goal setting & (b) building self-efficacy.Interim 1 lasts 14 days & begins 10-17 days before Study Visit 1.
Other: prolonged overnight fasting
Adherence to fasting will be estimated by proportion of the 49 nights (7 weeks) with ≥12 hours of fasting as per text message data from the participant. If the participant neglects to text the fasting duration, that night will be considered not adherent (a conservative adherence estimate).

Primary Outcome Measures :
  1. measure of glucose metabolism [ Time Frame: after 6 months ]
    Assess the effect of prolonged overnight fasting on glucose metabolism, measured by glycosylated hemoglobin (HbA1c).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body mass index is ≥ 25kg/m^2
  • History of treatment for cancer or related illness diagnosed at ≤ 25 years old
  • Off of all cancer therapy for ≥ 2 years (exluding treatment for non-invasive or superficial cancers)
  • Current age ≥ 18 years
  • English-speaking
  • Personal phone with SMS text messaging capability
  • Able to perform all study requirements

Exclusion Criteria:

  • Use of any antidiabetic, weight loss, or appetite control medication
  • Use of any other medication that could impact dietary intake, such as prednisone
  • Currently fasts 12 hours or more (on either of two 24 hour diet recalls, conducted during Interim 1)
  • Unable to fast due to medical reason such as pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03523377

Layout table for location information
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Rockefeller University
University of California
Layout table for investigator information
Principal Investigator: Emily Tonorezos Memorial Sloan Kettering Cancer Center
  Study Documents (Full-Text)

Documents provided by Memorial Sloan Kettering Cancer Center:
Informed Consent Form  [PDF] September 18, 2018

Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT03523377    
Other Study ID Numbers: 18-199
First Posted: May 14, 2018    Key Record Dates
Last Update Posted: June 12, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Memorial Sloan Kettering Cancer Center: